logo
Illinois presses pause on ‘critical' invasive carp project, cites federal funding concerns

Illinois presses pause on ‘critical' invasive carp project, cites federal funding concerns

Yahoo13-03-2025

GRAND RAPIDS, Mich. (WOOD) — Progress on the is once again at a stalemate, and several local lawmakers are calling on state officials in Illinois to help end delays for the project.
Funding agreement finally reached for $1.1 billion invasive carp project
The issued a statement to that effect earlier this week. The task force is comprised of lawmakers from both sides of the aisle, including U.S. Reps. Debbie Dingell, D-Ypsilanti, and Bill Huizenga, R-Holland.
'As Co-Chairs of the Great Lakes Task Force, we urge the state of Illinois to promptly sign the necessary documents and end further delays in the critical ecosystem protection construction at the Brandon Road Lock and Dam,' . 'This project is essential to prevent the spread of invasive carp throughout the Great Lakes. … Failing to do so puts the future of the Great Lakes ecosystem — and the multi-trillion-dollar economy it supports — at serious risk.'
The renovations at the Brandon Road Lock and Dam would prevent invasive carp from making their way from the Chicago Area Waterway System into Lake Michigan. The project has been studied and discussed for more than a decade. Illinois, Michigan and the U.S. Army Corps of Engineers last July after years of negotiations.
However, officials in Illinois have once again pressed pause over concerns that President Donald Trump will scale back federal funding.
Beyond Brandon Road: Monitoring 18 other points invasive carp could enter Great Lakes
A spokesperson for Illinois Gov. JB Pritzker that the governor 'agrees this project is critical to the Great Lakes,' but says he is concerned with the White House's recent trend of slashing federal funding.
Pritzker claims the White House has withheld $117 million in federal grants from the Illinois Department of Natural Resources, forcing it to freeze contracts and put nearly 70 other projects on hold.
'Until then, Gov. Pritzker must protect Illinois taxpayers from burdening the liability of the federal government not following through on their promises,' the spokesperson said. 'We cannot move forward until the Trump administration provides more certainty and clarity on whether they will follow the law and deliver infrastructure funds we were promised.'
First construction contract awarded on long-awaited $1.1 billion invasive carp project
As it stands now, the USACE is set to contribute $226 million toward the $1.14 billion project, using funds approved in the 2021 bipartisan infrastructure bill. Michigan had agreed to contribute $64 million in funding, and Illinois would provide $50 million.
As costly as the project may be, the threat of invasive carp could cost even more. — formerly known as Asian carp and also called — are considered a major threat to the Great Lakes because they could upend the natural ecosystem. They are voracious eaters and would devour the food sources for several popular Great Lakes fish, including walleye and rainbow trout, key players in the region's fishing industry.
Invasive carp were used as a tool in the 1970s, controlling algae, weed and parasite growth on aquatic farms. But the fish eventually made their way into the Mississippi River basin and now dominate that ecosystem.
Illinois DNR announces new name for invasive carp
The U.S. Army Corps of Engineers has worked with environmental agencies for years to monitor the fish in the Mississippi River basin and ensure they don't make it to the Great Lakes. The two systems only have one permanent connection point — the Chicago-Area Waterway System.
There are already multiple tools in place at the Brandon Road Lock and Dam to target invasive carp, including an electric barrier that costs Illinois taxpayers approximately $15 million each year.
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Why This Five-Star Analyst Hiked His Price Target on D-Wave Quantum Stock (QBTS)
Why This Five-Star Analyst Hiked His Price Target on D-Wave Quantum Stock (QBTS)

Business Insider

time30 minutes ago

  • Business Insider

Why This Five-Star Analyst Hiked His Price Target on D-Wave Quantum Stock (QBTS)

Quantum computing stock D-Wave Quantum (QBTS) has seen its stock soar over the past year, thanks to a massive 1,174% rally. Despite this, five-star Roth MKM analyst Sujeeva De Silva hiked his price target on QBTS stock from $12 to $18 on Friday, while maintaining a Buy rating. Confident Investing Starts Here: Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter It is worth noting that De Silva ranks 101 out of more than 9,621 analysts tracked by TipRanks and has a success rate of 51%, with an average return per rating of 26% over a one-year timeframe. Demand for Quantum Computing Is Gaining Traction According to De Silva, demand for quantum computing is gaining traction across both commercial and AI-related sectors, and D-Wave is well-placed to benefit from this trend. The analyst noted that customer interest has grown in recent months, especially in areas like hosted services and hardware sales, which could help expand the company's revenue base over time. He also pointed to the rising engagement from the AI space, where quantum computing is gaining attention as a tool to improve certain performance steps. As AI use cases become more complex, demand for D-Wave's offerings could grow. On the hardware front, the analyst said that D-Wave's first sale of its Advantage system to a key customer is a good early sign. He believes that the company could secure more hardware deals going forward, with future sales possibly coming at higher price points. With the new Advantage 2 system now officially launched, De Silva thinks that hardware talks could move more quickly toward actual deals. While De Silva admits the $18 price target reflects a 'significant multiple,' he believes that it is justified. If D-Wave is able to close several hardware deals each year, future revenue could better support the current valuation. As a result, in his view, D-Wave stands out as one of the most compelling players in the fast-growing world of quantum computing and AI. Is D-Wave a Good Stock to Buy? Overall, analysts have a Strong Buy consensus rating on QBTS stock based on six Buys assigned in the past three months, as indicated by the graphic below. Furthermore, the average QBTS price target of $14.20 per share implies 11.3% downside risk.

Jamba® Expands Beyond Storefronts with Rapidly Growing Retail Lineup
Jamba® Expands Beyond Storefronts with Rapidly Growing Retail Lineup

Yahoo

time2 hours ago

  • Yahoo

Jamba® Expands Beyond Storefronts with Rapidly Growing Retail Lineup

Iconic Smoothie Brand Hits Grocery Aisles and Doorsteps with Fan-Favorite Flavors ATLANTA, June 17, 2025--(BUSINESS WIRE)--Jamba, one of the seven iconic brands within the GoTo Foods platform company, continues to expand its footprint beyond traditional storefronts through strategic retail partnerships, driven by the Retail Licensing Division at GoTo Foods. Through these partnerships, Jamba is making smoothie-inspired flavors more accessible to fans across the US and Canada. From grocery aisles to online carts, the innovative Jamba product formats meet rising demand for on-the-go options: making it easier for fans to celebrate their brightest self with Jamba anytime, anywhere. This growing portfolio now includes drink mixes, frozen smoothie kits, fruit snacks, and direct-to-consumer smoothie boxes - each designed to meet consumers where they are and offer the vibrant flavors Jamba is known for. Jamba Singles to Go! Drink Mix Sticks Launched in partnership with The Jel Sert Company, these individually wrapped drink mix sticks allow consumers to enjoy Jamba on-the-go. Available in 3 Jamba-inspired flavors, Razzmatazz®, Mango-a-Go-Go®, and Strawberries Wild®, the low-calorie packets offer 3g of energy, essential vitamins, and convenience in every sip. Now available on Amazon. Jamba At Home Smoothie Kits Jamba At Home Smoothies will soon offer a ready-to-blend solution for fans craving their favorite flavors at home. Each kit will feature pre-packed frozen fruit and new BOOSTED cubes containing functional benefits like protein, vitamins, minerals and antioxidants. With 9-13g of protein per pack in iconic Jamba flavors like Orange Dream Machine®, Strawberries Wild®, and Razzmatazz®, these convenient, easy-to-make kits offer a quick delicious way to power your day, ideal for breakfast, post-workout, or any time in between. Jamba Fruit Flavored Snacks A few aisles down, Jamba Fruit Snacks transform smoothie-inspired flavors into chewy, melt-in-your-mouth gummies. Available in Mango-a-Go-Go™ and Strawberry Surf Rider™, these vibrant treats offer a new way to enjoy the bold, fruity taste of Jamba - no blender required. Available at grocery stores nationwide. Direct-to-Door Smoothie Innovation with Jamba x Revive Superfoods Smoothie Boxes Continuing their successful partnership, Jamba and Revive Superfoods have expanded their co-branded smoothie line with two new offerings: Raspberry Lychee and Banana Mocha. These join Tropical Strawberry and Apple Matcha to round out a four-flavor lineup of ready-to-blend, no-sugar-added smoothies delivered straight to the homes of consumers. Jamba fans now have the option to order individual, ready-to-blend smoothie cups or select the one-click Jamba box featuring the complete Jamba x Revive flavor lineup. All Jamba x Revive offerings are portioned for convenience and optimized for nutritious, flavorful enjoyment at home. More information is available at Revive Superfoods. "We're always looking for exciting, meaningful ways to grow our brands and a multi-channel approach is a powerful strategy," said Dave Mikita, President of International and Retail Channels at GoTo Foods. "We're meeting our fans where they are and making it easier than ever to enjoy Jamba, wherever life takes them." With these innovations, Jamba is rapidly redefining how and where fans engage with the brand, bringing the smoothie shop experience to grocery aisles, freezers, pantries, and doorsteps nationwide. About Jamba® Founded in 1990, Jamba is a leading global lifestyle brand that specializes in serving freshly blended fruit and vegetable smoothies, made-to-order bowls, fresh-squeezed juices and shots, as well as boosts and bites for those on the go. As of March 30, 2025, Jamba had over 770 locations across 34 U.S. states, along with presence in South Korea, the Philippines, Taiwan, Singapore, Australia, Guatemala and Saudi Arabia. Join Jamba rewards for special offers. For more information, visit or connect with us on Facebook, Instagram, TikTok or X. About GoTo Foods Atlanta-based platform company GoTo Foods LLC (formerly known as Focus Brands) is a leading developer of global multi-channel foodservice brands. As of March 30, 2025, GoTo Foods, through its affiliate brands, is the franchisor and operator of over 6,900 restaurants, cafes, ice cream shoppes and bakeries in all 50 states and over 65 countries and territories under the Auntie Anne's®, Carvel®, Cinnabon®, Jamba®, Moe's Southwest Grill®, McAlister's Deli® and Schlotzsky's® brand names, as well as the Seattle's Best Coffee® brand on certain military bases and in certain international markets. The iconic GoTo Foods brands benefit from strong enterprise growth engines, including marketing, digital, technology and franchise sales & development to propel growth and brand performance. Please visit and connect with us on LinkedIn to learn more. GoTo Foods is proud to be Certified™ by Great Place To Work®, the most definitive "employer-of-choice" recognition, and the only recognition based entirely on what employees report about their workplace experience for the second consecutive year. View source version on Contacts Media Contact Kalia Beard, GoTo Foods Director Retail Channels Licensing PR – press@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

PolyPid Secures $26.7 Million Through Warrant Exercise Following Successful SHIELD II Phase 3 Trial Results
PolyPid Secures $26.7 Million Through Warrant Exercise Following Successful SHIELD II Phase 3 Trial Results

Yahoo

time4 hours ago

  • Yahoo

PolyPid Secures $26.7 Million Through Warrant Exercise Following Successful SHIELD II Phase 3 Trial Results

The Company Anticipates that with this Additional Funding, PolyPid's Runway would be Extended beyond Anticipated U.S. Food and Drug Administration ('FDA') Approval of D-PLEX₁₀₀. The Company Recently Announced Successful Topline Results from its Phase 3 SHIELD II Trial; D-PLEX₁₀₀ Demonstrated a Statistically Significant Reduction in Surgical Site Infections ('SSIs') and Successfully Met the Study's Primary Endpoint and all Key Secondary Endpoints. PETACH TIKVA, Israel, June 17, 2025 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) ('PolyPid' or the 'Company'), a late-stage biopharma company aiming to improve surgical outcomes, today announced that following its recently announced successful SHIELD II phase 3 topline results, it has secured additional funding through the exercise of warrants with aggregate gross proceeds of $26.7 million. The Company anticipates that with this additional funding, PolyPid's runway would be extended beyond anticipated FDA approval of D-PLEX₁₀₀. The funding was secured through new agreements the Company has entered into with certain holders of its existing warrants for the immediate exercise of certain outstanding warrants to purchase up to an aggregate of 7,626,514 ordinary shares, no par value, of the Company originally issued in January 2024 and December 2024. As part of the new agreements, the warrants will be exercised at a price of $3.50 per share. The aggregate gross proceeds from the exercise of the existing warrants are expected to total $26.7 million. In consideration for the immediate exercise of the warrants for cash, the Company will issue 7,626,514 new unregistered warrants to purchase ordinary shares. The new warrants will be exercisable for an aggregate of up to 7,626,514 ordinary shares, at an exercise price of $4.50 per share and will be immediately exercisable upon issuance and for a term of two years from the issuance date. As part of the terms of the financing, it has been agreed that if the holder transfers/sells any of the shares acquired upon exercise of the existing warrants prior to the expiration or exercise of the new warrants, the new warrants shall immediately and automatically terminate and be forfeited with respect to the corresponding number of shares sold, unless such new warrants are concurrently exercised. The transaction is expected to close on or about June 18, 2025, subject to satisfaction of customary closing conditions. PolyPid intends to use the net proceeds from the offering for its new drug application ('NDA') submission, launch preparations, working capital and general corporate purposes. The new warrants described above were offered in a private placement pursuant to under Section 4(a)(2) of the Securities Act of 1933, as amended (the '1933 Act') and, along with the ordinary shares issuable upon their exercise, have not been registered under the 1933 Act, and may not be offered or sold in the United States absent registration with the Securities and Exchange Commission ('SEC') or an applicable exemption from such registration requirements. The Company has agreed to file a registration statement with the SEC covering the resale of the ordinary shares issuable upon exercise of the new warrants. This press release shall not constitute an offer to sell or a solicitation of an offer to buy nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction. About D-PLEX₁₀₀D-PLEX₁₀₀, PolyPid's lead product candidate, is designed to provide local prolonged and controlled anti-bacterial activity directly at the surgical site to prevent SSIs. Following the administration of D-PLEX₁₀₀ into the surgical site, the PLEX (Polymer-Lipid Encapsulation matriX) technology pairs with Active Pharmaceutical Ingredients, enabling a prolonged and continuous release of the broad-spectrum antibiotic doxycycline, resulting in a high local concentration of the drug for a period of 30 days for the prevention of SSIs, with additional potential to prevent SSIs caused by antibiotic-resistant bacteria at the surgical site. D-PLEX₁₀₀ received Breakthrough Therapy designation from the U.S. Food and Drug Administration for the prevention of SSIs in patients undergoing elective colorectal surgery. PolyPid recently announced successful topline results from its Phase 3 SHIELD II trial. In this study, D-PLEX₁₀₀ demonstrated a statistically significant reduction in SSIs and successfully met the study's primary endpoint and all key secondary endpoints. About PolyPidPolyPid Ltd. (Nasdaq: PYPD) is a late-stage biopharma company aiming to improve surgical outcomes. Through locally administered, controlled, prolonged-release therapeutics, PolyPid's proprietary PLEX (Polymer-Lipid Encapsulation matriX) technology pairs with Active Pharmaceutical Ingredients (APIs), enabling precise delivery of drugs at optimal release rates over durations ranging from several days to months. PolyPid's lead product candidate, D-PLEX₁₀₀, demonstrated a statistically significant reduction in SSIs and successfully met the primary endpoint and all key secondary endpoints in the SHIELD II Phase 3 clinical trial. In addition, the Company is currently in preclinical stages to test the efficacy of OncoPLEX for the treatment of solid tumors, beginning with glioblastoma. For additional Company information, please visit and follow us on Twitter and LinkedIn. Forward-looking StatementsThis press release contains 'forward-looking statements' within the meaning of the Private Securities Litigation Reform Act and other securities laws. Words such as 'expects,' 'anticipates,' 'intends,' 'plans,' 'believes,' 'seeks,' 'estimates' and similar expressions or variations of such words are intended to identify forward-looking statements. For example, the Company is using forward-looking statements when it discusses its expected cash runway, the expected closing date of the warrant inducement transaction, the use of proceeds, potential NDA submission and potential clinical benefits of D-PLEX₁₀₀, including safety and efficacy. Forward-looking statements are not historical facts, and are based upon management's current expectations, beliefs and projections, many of which, by their nature, are inherently uncertain. Such expectations, beliefs and projections are expressed in good faith. However, there can be no assurance that management's expectations, beliefs and projections will be achieved, and actual results may differ materially from what is expressed in or indicated by the forward-looking statements. Forward-looking statements are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in the forward-looking statements. For a more detailed description of the risks and uncertainties affecting the Company, reference is made to the Company's reports filed from time to time with the SEC, including, but not limited to, the risks detailed in the Company's Annual Report on Form 20-F filed on February 26, 2025. Forward-looking statements speak only as of the date the statements are made. The Company assumes no obligation to update forward-looking statements to reflect actual results, subsequent events or circumstances, changes in assumptions or changes in other factors affecting forward-looking information except to the extent required by applicable securities laws. If the Company does update one or more forward-looking statements, no inference should be drawn that the Company will make additional updates with respect thereto or with respect to other forward-looking statements. References and links to websites have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release. PolyPid is not responsible for the contents of third-party websites. Contacts: PolyPid Ltd. Ori WarshavskyCOO – US908-858-5995IR@ Investors:Brian RitchieLifeSci Advisors212-915-2578BRitchie@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store